CHROMOGRANIN-A IMMUNOREACTIVITY IN HUMAN CEREBROSPINAL-FLUID - PROPERTIES, RELATIONSHIP TO NORADRENERGIC NEURONAL-ACTIVITY, AND VARIATION IN NEUROLOGIC DISEASE
Dt. Oconnor et al., CHROMOGRANIN-A IMMUNOREACTIVITY IN HUMAN CEREBROSPINAL-FLUID - PROPERTIES, RELATIONSHIP TO NORADRENERGIC NEURONAL-ACTIVITY, AND VARIATION IN NEUROLOGIC DISEASE, Neuroscience, 56(4), 1993, pp. 999-1007
Although measurement of chromogranin A in the bloodstream is of value
in sympathoadrenal investigations, little is systematically known abou
t chromogranin A in cerebrospinal fluid, despite substantial knowledge
about its occurrence and distribution in brain. We therefore applied
a homologous human chromogranin A radioimmunoassay to cerebrospinal fl
uid, in order to evaluate the properties and stability of cerebrospina
l fluid chomogranin A, as well as its relationship to central noradren
ergic neuronal activity, to peripheral (plasma) chromogranin A, and to
disease states such as hypertension, renal failure and Parkinsonism.
Authentic, physically stable chromogranin A immunoreactivity was found
in cerebrospinal fluid (at 37-146 ng/ml; mean, 87.0 +/- 6.0 ng/ml in
healthy subjects), and several lines of evidence (including 3.39 +/- 0
.27-fold higher chromogranin A in cerebrospinal fluid than in plasma)
indicated that it originated from a local central nervous system sourc
e, rather than the periphery. Cerebrospinal fluid chromogranin A value
s were not influenced by administration of effective antihypertensive
doses of clonidine or propranolol, and were not related to the cerebro
spinal fluid concentrations of norepinephrine, methoxyhydroxyphenylgly
col, or dopamine-beta-hydroxylase; thus, cerebrospinal fluid chromogra
nin A was not closely linked to biochemical or pharmacologic indices o
f central noradrenergic neuronal activity. Cerebrospinal fluid chromog
ranin A was not changed (P > 0. 1) in essential hypertension (84.2 +/-
14.0 ng/ml) or renal failure (72.2 +/- 13.4 ng/ml), despite a marked
(7.1-fold; P < 0.001) increase in plasma chromogranin A in renal failu
re, and a modest (1.5-fold; P = 0.004) increase in plasma chromogranin
A in essential hypertension. In Parkinson's disease, a diminution (2.
8-fold; P < 0.001) of cerebrospinal fluid chromogranin A may be of dia
gnostic value.